Device type · PFF
High Throughput Dna Sequence Analyzer
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
PFF
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
1
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- High Throughput Dna Sequence Analyzer
- Product code
- PFF
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.2265
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for PFF
Latest FDA decisions
- Ion PGM Dx System510(k)
K170299 · Decided Jun 22, 2017 · 142 days after receipt
Device type: High Throughput Dna Sequence Analyzer (PFF) · Laboratory Medicine & Pathology
Reports received
1
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
0.0% of reports
Injury reports
1
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 1 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 1 | 1 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 1 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Device Fell1
- Leak/Splash1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Chemical Exposure1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Ion Torrent Genexus Dx with software, Catalog: A40003539, which supports the Ion Torrent Genexus Dx Integrated SequencerOpen, Classified
Life Technologies Holdings Pte Ltd
Z-0211-2027 · Started Aug 14, 2026 · Posted by FDA Oct 22, 2026
Reason given: DNA or RNA sequencing system software has vulnerabilities.
Cause as FDA categorized it: Software design
- NovaSeq 6000Dx including DRAGEN Server, Catalog Number: 20068232; Illumina DRAGEN Server for NextSeq 550Dx, Catalog Number: 20086130Open, Classified
Z-0068-2027 · Started Sep 17, 2024 · Posted by FDA Oct 1, 2026
Reason given: Retrospectively reported correction for an instrument intended for targeted sequencing of DNA libraries from human genomic DNA used with in vitro diagnostic assays has a server with a security vulnerability.
Cause as FDA categorized it: Software design
Z-0320-2027 · Started May 8, 2024 · Posted by FDA Oct 30, 2026
Reason given: (Retrospectively reported) Cybersecurity vulnerability identified in communication protocol between the customer-provided infrastructure (network storage, servers, or computers) and in vitro diagnostic devices which may result in compromised data transmission.
Cause as FDA categorized it: Labeling design
15 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.